Clinical trials: Hepatitis C Virus
Hepatitis C, Drug Use
Future Destinations: Journeys Towards Citizenship
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), if left untreated it can lead to chronic liver disease, cirrhosis and cancer.
- Trial name
- NCT04159545
- Testing
- Qualitative and quantitative interviews
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Dundee
Chronic Hepatitis C Infection
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin…
- Trial name
- ZIRCON (NCT02486406)
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 64 people
- Sponsor
- AbbVie
Hepatitis C, Chronic, Substance Abuse Treatment Centers
Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland
Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine.
- Conditions
- Hepatitis C, Chronic, Substance Abuse Treatment Centers, Opioid-Related Disorders
- Trial name
- HepCOP (NCT00473993)
- Sponsor
- Seidenberg, Arztpraxis A., M.D.
Chronic Hepatitis C Virus
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.
- Trial name
- NCT02629172
- Where
- 388 sites in Japan
- Volunteers
- 3,043 people
- Sponsor
- AbbVie
Hepatitis C
Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies
To generate a library of genes that reflect the entirety of antibody responses to hepatitis C virus (HCV) made during the 20-year course of HCV infection in a single patient (WH) whose viral quasispecies has been extensively…
- Trial name
- NCT00004851
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Substance-Related Disorders, Hepatitis
Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users
Injection drug use accounts for transmission of a high proportion of Hepatitis C Virus (HCV) infections. The purpose of this trial is to investigate the effectiveness of pegylated interferon in treating injection drug users…
- Trial name
- NCT00194480
- Testing
- Pegylated Interferon
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Hepatitis C Virus
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a…
- Trial name
- PEDESTAL (NCT01598090)
- Testing
- Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin
- Where
- 104 sites in United States, Austria and 13 more
- Volunteers
- 881 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C Infection
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
This is a multi-centre prospective longitudinal cohort study with the aim of collecting and storing clinical data, patient blood, DNA and PBMCs to examine outcomes related to drug resistance, drug monitoring and host genetics in…
- Trial name
- SEARCH-C (NCT02065999)
- Where
- 2 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Kirby Institute